Altimmune, Inc. Stock News

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.41% to 32,376.61 while the NASDAQ rose 1.05% to 11,798.39. T

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. Impac Mortgage Holdings, Inc. (NYSE:

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.65% to 32,455.57 while the NASDAQ rose 0.57% to 11,741.91. The S&P 500

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.90% to 32,535.25 while the NASDAQ rose 1.0

Altimmune (NASDAQ: ALT ) stock is losing value on Tuesday after the company released results from a clinical trial. That trial has to do with the company's treatment for obesity.

Altimmune (NASDAQ:ALT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0

Altimmune is a pioneer in creating peptide-based therapies for obesity and liver disease, with a unique approach to product development. Altimmune's R&D expenses have dropped year-on-year due to the d

Altimmune has exposure to promising growth areas of obesity and non-alcoholic liver disease treatment. Upcoming trial data and proof of concept work for its pemvidutide compound is key to see the stoc

GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2

GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 202

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.

Within the last quarter, Altimmune (NASDAQ:ALT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1

Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.